Insider Trading Alert - CNQR, EPAM, CRM, DLX And BSX Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Dec. 2, 2013, 167 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $696.00 to $31,440,000.00.

Highlighted Stocks Traded by Insiders:

Concur Technologies (CNQR) - FREE Research Report

Singh Sudhir Steven who is CEO + Chairman at Concur Technologies sold 10,000 shares at $95.58 on Dec. 2, 2013. Following this transaction, the CEO + Chairman owned 991,501 shares meaning that the stake was reduced by 1% with the 10,000-share transaction.

The shares most recently traded at $93.49, down $2.09, or 2.23% since the insider transaction. Historical insider transactions for Concur Technologies go as follows:

  • 4-Week # shares sold: 4,175
  • 12-Week # shares sold: 25,175
  • 24-Week # shares sold: 123,629

The average volume for Concur Technologies has been 533,600 shares per day over the past 30 days. Concur Technologies has a market cap of $5.4 billion and is part of the technology sector and computer software & services industry. Shares are up 43.79% year-to-date as of the close of trading on Monday.

Concur Technologies, Inc. provides integrated travel and expense management solutions for companies worldwide. Currently there are 5 analysts that rate Concur Technologies a buy, 2 analysts rate it a sell, and 10 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CNQR - FREE

TheStreet Quant Ratings rates Concur Technologies as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and growth in earnings per share. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity and weak operating cash flow. Get the full Concur Technologies Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

EPAM Systems (EPAM) - FREE Research Report

Robb Karl who is President of EU Operations,EVP at EPAM Systems sold 789 shares at $35.15 on Dec. 2, 2013. Following this transaction, the President of EU Operations,EVP owned 0 shares meaning that the stake was reduced by 100% with the 789-share transaction.

The shares most recently traded at $35.45, up $0.30, or 0.85% since the insider transaction. Historical insider transactions for EPAM Systems go as follows:

  • 4-Week # shares sold: 2.5 million
  • 12-Week # shares sold: 3.1 million
  • 24-Week # shares sold: 6.6 million

The average volume for EPAM Systems has been 407,500 shares per day over the past 30 days. EPAM Systems has a market cap of $1.6 billion and is part of the technology sector and computer software & services industry. Shares are up 95.86% year-to-date as of the close of trading on Monday.

EPAM Systems, Inc., together with its subsidiaries, primarily provides software product development services worldwide. The company has a P/E ratio of 29.1. Currently there are 5 analysts that rate EPAM Systems a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on EPAM - FREE

TheStreet Quant Ratings rates EPAM Systems as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and growth in earnings per share. However, as a counter to these strengths, we find that the company's return on equity has been disappointing. Get the full EPAM Systems Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Salesforce.com (CRM) - FREE Research Report

Conway Craig who is Director at Salesforce.com sold 1,600 shares at $52.00 on Dec. 2, 2013. Following this transaction, the Director owned 17,456 shares meaning that the stake was reduced by 8.4% with the 1,600-share transaction.

The shares most recently traded at $51.39, down $0.61, or 1.19% since the insider transaction. Historical insider transactions for Salesforce.com go as follows:

  • 4-Week # shares sold: 1,600
  • 12-Week # shares sold: 39,476
  • 24-Week # shares sold: 53,876

The average volume for Salesforce.com has been 5.1 million shares per day over the past 30 days. Salesforce.com has a market cap of $31.4 billion and is part of the technology sector and computer software & services industry. Shares are up 23.95% year-to-date as of the close of trading on Monday.

salesforce.com, inc. provides enterprise cloud computing solutions to various businesses and industries worldwide. Currently there are 22 analysts that rate Salesforce.com a buy, 1 analyst rates it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CRM - FREE

TheStreet Quant Ratings rates Salesforce.com as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and compelling growth in net income. However, as a counter to these strengths, we find that the company has favored debt over equity in the management of its balance sheet. Get the full Salesforce.com Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Deluxe Corporation (DLX) - FREE Research Report

McGrath Don J who is Director at Deluxe Corporation sold 5,000 shares at $49.70 on Dec. 2, 2013. Following this transaction, the Director owned 32,499 shares meaning that the stake was reduced by 13.33% with the 5,000-share transaction.

The shares most recently traded at $48.55, down $1.16, or 2.38% since the insider transaction. Historical insider transactions for Deluxe Corporation go as follows:

  • 4-Week # shares sold: 6,500
  • 12-Week # shares sold: 29,500
  • 24-Week # shares sold: 38,938

The average volume for Deluxe Corporation has been 333,800 shares per day over the past 30 days. Deluxe Corporation has a market cap of $2.5 billion and is part of the services sector and diversified services industry. Shares are up 54.13% year-to-date as of the close of trading on Monday.

Deluxe Corporation, together with its subsidiaries, provides printed products, forms, and marketing solutions to small businesses and financial institutions primarily in the United States, Canada, Europe, and South America. The stock currently has a dividend yield of 2.01%. The company has a P/E ratio of 13.9. Currently there is 1 analyst that rates Deluxe Corporation a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on DLX - FREE

TheStreet Quant Ratings rates Deluxe Corporation as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, growth in earnings per share, attractive valuation levels and good cash flow from operations. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Deluxe Corporation Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Boston Scientific (BSX) - FREE Research Report

Capello Jeffrey D who is EVP & Chief Financial Officer at Boston Scientific sold 108,595 shares at $11.70 on Dec. 2, 2013. Following this transaction, the EVP & Chief Financial Officer owned 447 shares meaning that the stake was reduced by 99.59% with the 108,595-share transaction.

The shares most recently traded at $11.65, down $0.05, or 0.43% since the insider transaction. Historical insider transactions for Boston Scientific go as follows:

  • 4-Week # shares sold: 233,071
  • 12-Week # shares sold: 242,307
  • 24-Week # shares sold: 339,680

The average volume for Boston Scientific has been 13.9 million shares per day over the past 30 days. Boston Scientific has a market cap of $15.5 billion and is part of the health care sector and health services industry. Shares are up 102.09% year-to-date as of the close of trading on Monday.

Boston Scientific Corporation develops, manufactures, and markets medical devices used in various interventional medical specialties worldwide. Currently there are 4 analysts that rate Boston Scientific a buy, no analysts rate it a sell, and 15 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BSX - FREE

TheStreet Quant Ratings rates Boston Scientific as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, compelling growth in net income, expanding profit margins and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Boston Scientific Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Data for this article provided by Zacks Investment Research

null

More from Markets

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists